Table 2.
The List of Some Clinical Trials Using Mesenchymal Stem Cells to Treat Intrauterine Adhesions (or Thin Endometrium, Asherman’s Syndrome). All Data Come From: Home - ClinicalTrials.gov.
| Pathological condition | Cell therapy | Estimated enrollment | Intervention/treatment | Cliniclatrials.gov identifier | Outcome measures |
|---|---|---|---|---|---|
| Infertile women with severe intrauterine adhesions or endometrial dysplasia | Collagen scaffold loaded with autologous BMSCs | 30 participants | Autologous bone marrow stem cells | NCT02204358 | Evaluation of the reduction of intrauterine scar area, the change of intrauterine adhesion, endometrial thickness, and the menstrual blood volume |
| Women with intrauterine adhesion | UC-MSCs loaded in collagen scaffold | 18 participants | UCMSC combined with collagen scaffold | NCT03724617 | Evaluation of the change of endometrial thickness, pregnancy rate, live birth rate, abortion rate |
| Women with scarring and adhesions | AMSCs and a biodegradable carrier | 10 participants | Autologous mesenchymal stem cells | NCT04432467 | Evaluation of the number of cured patients, and patients with treatment-related adverse events |
| Women infertility with severe refractory Asherman’s syndrome | hAESCs | 50 participants | hAESCs-based therapy | NCT03223454 | Evaluation of menstrual blood volume, Endometrial thickness, Uterine volume, Ongoing pregnancy rate |
| Women with severe refractory Asherman’s syndrome | hAESCs | 20 participants | hAESCs-based therapy | NCT03381807 | Evaluation of the changes of Endometrial thickness, Menstrual blood volume, pregnancy rate |
| Infertility women with Intrauterine adhesions | UCMSCs | 26 participants | UCMSC-based therapy | NCT02313415 | Evaluation of live birth rate, endometrial thickness, reduction of intrauterine adhesion, change of menstrual blood volume |
| Patients with Asherman’s Syndrome | CD133+ autologous BMSCs | 16 participants | Bone marrow CD133+ stem cell transplantation | NCT02144987 | Evaluation of Live-birth rate, Ongoing pregnancy rate, Implantation Rate, Endometrial thickness prior to the treatment |
| Asherman Syndrome Endometrium Recurrent Implantation Failure |
Autologous BMSCs | 30 participants | BMSCs-based therapy | NCT05343572 | Evaluation of endometrial thickness and implantation rates |
AMSCs: adipose tissue derived mesenchymal stem cells; BMSCs: bone marrow stem cells; hAESCs: Human amniotic epithelial stem cells; UCMSC: umbilical cord mesenchymal stem cells.